Posted by Michael Wonder on 20 May 2024
Will Erbitux’s reimbursement be expanded to first-line treatment of colorectal cancer?
17 May 2024 - Attention is on whether Merck's colorectal cancer drug, Erbitux (cetuximab), can expand its reimbursement following the latest change in its approval conditions.
At its fifth meeting for this year on 2 May, the Pharmaceutical Reimbursement Evaluation Committee (PREC) under the Health Insurance Review and Assessment Service conditionally passed the proposal to expand the reimbursement criteria for Erbitux.
